MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Krüppel-like factor 4

Cancer Letters

Volumn 355, Issue 1, 2014, Pages 85-95

  Ma, Jun ^a   Yao, Yilong ^a   Wang, Ping ^a   Liu, Yunhui ^a   Zhao, Lini ^a   Li, Zhiqing ^a   Li, Zhen ^a   Xue, Yixue ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Glioblastoma; KLF4; MicroRNAs; MiR 152; Stem cells

Indexed keywords

GALECTIN 3; KRUPPEL LIKE FACTOR 4; MICRORNA; MICRORNA 152; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; GALECTIN-3, HUMAN; KRUPPEL LIKE FACTOR; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; MIRN152 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; CANCER STEM CELL; CANCER SURVIVAL; CELL INVASION; CELL ISOLATION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE FUNCTION; GENE INTERACTION; GENE OVEREXPRESSION; GENE TARGETING; GLIOBLASTOMA STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; INTRACELLULAR SIGNALING; PROTEIN TARGETING; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; ANIMAL; BAGG ALBINO MOUSE; BRAIN TUMOR; CELL MOTION; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; GLIOBLASTOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TIME; TUMOR CELL CULTURE; TUMOR INVASION;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; GALECTIN 3; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GLIOBLASTOMA; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; TUMOR CELLS, CULTURED;

EID: 84907972096     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.09.012     Document Type: Article

References (54)

1. Clarke J., Butowski N., Chang S. Recent advances in therapy for glioblastoma. Arch. Neurol 2010, 67:279-283.
2. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics, 2006, CA Cancer J. Clin 2006, 56:106-130.
3. Liu H.L., Fan C.H., Ting C.Y., Yeh C.K. Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview. Theranostics 2014, 4:432-444.
4. Galli R., Binda E., Orfanelli U., Cipelletti B., Gritti A., De Vitis S., et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004, 64:7011-7021.
5. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
6. Piccirillo S.G., Binda E., Fiocco R., Vescovi A.L., Shah K. Brain cancer stem cells. J. Mol. Med. (Berl.) 2009, 87:1087-1095.
7. Sanchez-Martin M. Brain tumour stem cells: implications for cancer therapy and regenerative medicine. Curr. Stem Cell Res. Ther 2008, 3:197-207.
8. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
9. Jimenez-Mateos E.M., Henshall D.C. Epilepsy and microRNA. Neuroscience 2013, 238:218-229.
10. Nimmo R.A., Slack F.J. An elegant miRror: microRNAs in stem cells, developmental timing and cancer. Chromosoma 2009, 118:405-418.
11. Yang H., Li Q., Zhao W., Yuan D., Zhao H., Zhou Y. miR-329 suppresses the growth and motility of neuroblastoma by targeting KDM1A. FEBS Lett 2014, 588:192-197.
12. Ke Y., Zhao W., Xiong J., Cao R. Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells. FEBS Lett 2013, 587:3153-3157.
13. Baer C., Claus R., Plass C. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res 2013, 73:473-477.
14. Shi Y., Liu C., Liu X., Tang D.G., Wang J. The microRNA miR-34a inhibits non-small cell lung cancer (NSCLC) growth and the CD44hi stem-like NSCLC cells. PLoS ONE 2014, 9:e90022.
15. Liu T., Hou L., Huang Y. EZH2-specific microRNA-98 inhibits human ovarian cancer stem cell proliferation via regulating the pRb-E2F pathway. Tumour Biol 2014.
16. Zhang D., Yang G., Chen X., Li C., Wang L., Liu Y., et al. mir-300 promotes self-renewal and inhibits the differentiation of glioma stem-like cells. J. Mol. Neurosci 2014.
17. Chen Y., Song Y., Wang Z., Yue Z., Xu H., Xing C., et al. Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance. J. Gastrointest. Surg 2010, 14:1170-1179.
18. Wu Y., Huang A., Li T., Su X., Ding H., Li H., et al. MiR-152 reduces human umbilical vein endothelial cell proliferation and migration by targeting ADAM17. FEBS Lett 2014.
19. Gao J., Yang T., Han J., Yan K., Qiu X., Zhou Y., et al. MicroRNA expression during osteogenic differentiation of human multipotent mesenchymal stromal cells from bone marrow. J. Cell. Biochem 2011, 112:1844-1856.
20. Giraud-Triboult K., Rochon-Beaucourt C., Nissan X., Champon B., Aubert S., Pietu G. Combined mRNA and microRNA profiling reveals that miR-148a and miR-20b control human mesenchymal stem cell phenotype via EPAS1. Physiol. Genomics 2011, 43:77-86.
21. Merkerova M., Vasikova A., Belickova M., Bruchova H. MicroRNA expression profiles in umbilical cord blood cell lineages. Stem Cells Dev 2010, 19:17-26.
22. Xu Q., Jiang Y., Yin Y., Li Q., He J., Jing Y., et al. A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J. Mol. Cell. Biol 2013, 5:3-13.
23. Tsuruta T., Kozaki K., Uesugi A., Furuta M., Hirasawa A., Imoto I., et al. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res 2011, 71:6450-6462.
24. Zhou X., Zhao F., Wang Z.N., Song Y.X., Chang H., Chiang Y., et al. Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Oncol. Rep 2012, 27:447-454.
25. Braconi C., Huang N., Patel T. MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology 2010, 51:881-890.
26. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
27. Ma J., Wang P., Liu Y., Zhao L., Li Z., Xue Y. Kruppel-like factor 4 regulates blood-tumor barrier permeability via ZO-1, occludin and claudin-5. J. Cell. Physiol 2013.
28. Bresalier R.S., Yan P.S., Byrd J.C., Lotan R., Raz A. Expression of the endogenous galactose-binding protein galectin-3 correlates with the malignant potential of tumors in the central nervous system. Cancer 1997, 80:776-787.
29. Guvenc H., Pavlyukov M.S., Joshi K., Kurt H., Banasavadi-Siddegowda Y.K., Mao P., et al. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin. Cancer Res 2013, 19:631-642.
30. Karsy M., Arslan E., Moy F. Current progress on understanding MicroRNAs in glioblastoma multiforme. Genes Cancer 2012, 3:3-15.
31. Huang J., Wang Y., Guo Y., Sun S. Down-regulated microRNA-152 induces aberrant DNA methylation in hepatitis B virus-related hepatocellular carcinoma by targeting DNA methyltransferase 1. Hepatology 2010, 52:60-70.
32. Zheng X., Chopp M., Lu Y., Buller B., Jiang F. MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3. Cancer Lett 2013, 329:146-154.
33. Tetreault M.P., Yang Y., Katz J.P. Kruppel-like factors in cancer. Nat. Rev. Cancer 2013, 13:701-713.
34. McConnell B.B., Yang V.W. Mammalian Kruppel-like factors in health and diseases. Physiol. Rev 2010, 90:1337-1381.
35. Yamanaka S. Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 2007, 1:39-49.
36. Jiang J., Chan Y.S., Loh Y.H., Cai J., Tong G.Q., Lim C.A., et al. A core Klf circuitry regulates self-renewal of embryonic stem cells. Nat. Cell Biol 2008, 10:353-360.
37. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
38. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
39. Ohnishi K., Semi K., Yamamoto T., Shimizu M., Tanaka A., Mitsunaga K., et al. Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation. Cell 2014, 156:663-677.
40. Tai S.K., Yang M.H., Chang S.Y., Chang Y.C., Li W.Y., Tsai T.L., et al. Persistent Kruppel-like factor 4 expression predicts progression and poor prognosis of head and neck squamous cell carcinoma. Cancer Sci 2011, 102:895-902.
41. Yu F., Li J., Chen H., Fu J., Ray S., Huang S., et al. Kruppel-like factor 4 (KLF4) is required for maintenance of breast cancer stem cells and for cell migration and invasion. Oncogene 2011, 30:2161-2172.
42. Wong C.W., Hou P.S., Tseng S.F., Chien C.L., Wu K.J., Chen H.F., et al. Kruppel-like transcription factor 4 contributes to maintenance of telomerase activity in stem cells. Stem Cells 2010, 28:1510-1517.
43. Li Z., Zhao J., Li Q., Yang W., Song Q., Li W., et al. KLF4 promotes hydrogen-peroxide-induced apoptosis of chronic myeloid leukemia cells involving the bcl-2/bax pathway. Cell Stress Chaperones 2010, 15:905-912.
44. Barondes S.H., Cooper D.N., Gitt M.A., Leffler H. Galectins. Structure and function of a large family of animal lectins. J. Biol. Chem 1994, 269:20807-20810.
45. Hoyer K.K., Pang M., Gui D., Shintaku I.P., Kuwabara I., Liu F.T., et al. An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am. J. Pathol 2004, 164:893-902.
46. Vandenbrule F., Bellahcene A., Jackers P., Liu F., Sobel M., Castronovo V. Antisense galectin-3 alters thymidine incorporation in human MDA-MB435 breast cancer cells. Int. J. Oncol 1997, 11:261-264.
47. Honjo Y., Nangia-Makker P., Inohara H., Raz A. Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin. Cancer Res 2001, 7:661-668.
48. Yoshii T., Inohara H., Takenaka Y., Honjo Y., Akahani S., Nomura T., et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. Int. J. Oncol 2001, 18:787-792.
49. Liu F.T., Rabinovich G.A. Galectins as modulators of tumour progression. Nat. Rev. Cancer 2005, 5:29-41.
50. Takenaka Y., Fukumori T., Yoshii T., Oka N., Inohara H., Kim H.R., et al. Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol. Cell. Biol 2004, 24:4395-4406.
51. Ochieng J., Leite-Browning M.L., Warfield P. Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem. Biophys. Res. Commun 1998, 246:788-791.
52. Le Marer N., Hughes R.C. Effects of the carbohydrate-binding protein galectin-3 on the invasiveness of human breast carcinoma cells. J. Cell. Physiol 1996, 168:51-58.
53. Hood J.D., Cheresh D.A. Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2002, 2:91-100.
54. Elad-Sfadia G., Haklai R., Balan E., Kloog Y. Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J. Biol. Chem 2004, 279:34922-34930.